Operator's Information
Seung-Whan Lee, MD
| Country | Korea (Republic of) |
| Specialty | Interventional Cardiologist |
- Guidewire Updates: Concept and Technology
- Korea CTO Strategy of ADR
- Summary of CTO Technique for Beginners: We Can Do It.
- When and How to Change Your Plan A to Plan B
- The Contribution of Retrograde Approach in CTO PCI
- DECISION-CTO Trial: Updated QOL and Outcome Data
- Antegrade Approach in Korea 2018
- Expert Case Presentation: My Challenging CTO PCI
- DECISION-CTO Trial: Treat or Not Treat CTO
- LUTONIX Korean Registry Data
- The Lesson from DECISION-CTO Trial
- Carotid Artery Stenting; Indication & Technical Issue
- Comparable Impact of OMT After Failed Versus Successful CTO-PCI
- Class Effect of DCB?
- CTO-PCI: Simple Approach Has Evidence
- Full-Metal Jacket in CTO-PCI from AMC Registry: Safe or Not?
- How to Manage Complex SFA Lesions
- Should We Open Every CTO?: DECISION CTO
- IN PACT SFA Randomized Trial: DCB Becomes First Line Therapy
- TAVI for Patients with Peripheral Artery Disease
- Against: Don't Care of CTO Expertise
- Angiosome-based Intervention Is Associated with Improved Outcomes
- Medical Treatment of Symptomatic PAD: The Role of Cilostazol
- CTO: See the Unseen - Function Rather than Anatomy
- Clinical Data Update for DEB
- Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-V: Biolimus A9-Eluting (NOBORI) vs. Everolimus-eluting (PROMUS-ELEMENT) Stent: LONG V Trial Preliminary Data
- Asymptomatic Carotid Artery Stenosis: Is Really Risky? Must Be Recanalized?
- Cooler: Not Over till Over, PCI Is Getting Better!
- CTO-PCI: Success or Failure Doesn't Matter: From Asan CTO Registry
- BTK Intervention
- Triple Antiplatelet Therapy in DES Era: Default Strategy in High Risk Population
- Fielder XT: Initial and Professional Use for CTO
- Tailored Approach to Reduction of Restenosis after DES Implantation: Results from Pooled Analysis of DECLARE Trials
- Comparison of Sirolimus-eluting vs. Everolimus-eluting Stents in Diabetic and Non-Diabetic Patients: Results from the IRIS-DES Registry and the ESSENCE-DIABETES Clinical Trial
- Take Home Message with Special Lecture
- How & Why CTO?_Passion, Confidence, Success and Happiness
- Updated Data and Clinical Application of Triple Antiplatelet Therapy: The Answer to Patients with CYP 2C19 Polymorphism and High Post-Treatment Platelet Reactivity After Clopidogrel?
